What is the research dosage of thymosin alpha-1?

The dosing references converge on 1.6 mg given subcutaneously twice weekly, with a wider reported single-dose range of roughly 0.8 to 6.4 mg across studies. Study protocols have run the 1.6 mg twice-weekly schedule over about 24 weeks. These figures are reproduced strictly as a laboratory research reference and are not a human dosing protocol or medical advice.

Why is thymosin alpha-1 dosed on a schedule rather than titrated up?

Because the research interest is a sustained immunomodulatory signal over weeks rather than an acute pulse or a titration to a tolerance ceiling. That is why the reference is a fixed 1.6 mg twice weekly instead of an escalating ladder like a metabolic incretin.

What should a thymosin alpha-1 COA confirm?

The natural molecule is N-terminally acetylated, and a non-acetylated impostor is about 42 Da lighter — light enough to hide behind a clean HPLC purity peak. A meaningful certificate confirms the acetyl cap and the full 28-residue sequence by mass spectrometry and states the deamidation status, not just a purity percentage.

Is thymosin alpha-1 the same as TB-500?

No. Thymosin alpha-1 is a 28-residue immune peptide; TB-500 is derived from Thymosin Beta-4, a different and larger molecule. They share only a family name, and a dosing reference for one does not transfer to the other. Titan stocks a TB-500 vial but does not stock thymosin alpha-1.

Does Titan sell thymosin alpha-1?

No. Titan does not stock thymosin alpha-1. This page is an informational dosing reference; the honest catalog pointer is Titan's in-house-tested research peptides, and Titan does carry a separate TB-500 vial from the same broad thymosin family.

Thymosin alpha-1 · thymalfasin (Tα1) · research use only

Thymosin alpha-1 is dosed by a fixed amount on a set weekly rhythm, not a titration ladder.

Thymosin alpha-1 — thymalfasin, Tα1 — is a 28-amino-acid, N-terminally acetylated peptide first isolated from thymic fraction-5. Unlike a metabolic incretin that climbs a dose ladder, its research dosing is a fixed amount on a set rhythm: the clinical literature converges on 1.6 mg subcutaneously twice weekly, with the wider single-dose range reported roughly from 0.8 to 6.4 mg. This page reproduces those figures as a laboratory reference, explains why a defined immune peptide is dosed on a schedule rather than titrated, and covers the one verification point unique to this molecule — the N-terminal acetyl cap that a bare purity number can miss. Framed as a research reference, not a human protocol. Titan does not stock thymosin alpha-1; see the honest catalog pointer below.

Where to buy thymosin alpha-1 — sourcing & COA In-house-tested research peptides

1.6 mg subcutaneous, twice weekly

The dosing references converge on 1.6 mg given subcutaneously twice weekly — the figure the FDA bulk-substance bulletin and the review literature both cite, with study protocols running that schedule over 24 weeks. The broader single-dose range reported across studies is roughly 0.8 to 6.4 mg. Reproduced here strictly as a laboratory research reference for in-vitro and modelling work, not a human instruction.

Sourcing and COA notes →

Why it's a schedule, not a ladder

Metabolic peptides climb a tolerance-limited dose ladder; thymosin alpha-1 does not. It is dosed as a fixed amount on a fixed twice-weekly rhythm because the research interest is a sustained immunomodulatory signal over weeks, not a single acute pulse or a titration to a ceiling. That is why the reference reads '1.6 mg twice weekly' rather than 'escalate every four weeks'.

Reference framing →

Reconstitution math

Thymosin alpha-1 typically ships lyophilized and the working concentration is set by the diluent volume. As a worked example, a 10 mg vial in 2.5 mL of bacteriostatic water yields 4 mg/mL, so 0.4 mL on a U-100 insulin syringe draws the 1.6 mg reference figure. Confirm your own vial's stated mass and run the numbers before any in-vitro modelling rather than assuming a concentration.

Run the numbers →

The acetyl-cap COA check

The natural molecule is Nα-acetylated at its N-terminus. A non-acetylated impostor is about 42 Da lighter and can hide behind a clean HPLC 'purity' peak — so a meaningful certificate confirms the acetyl cap and the full 28-residue sequence by mass spectrometry, and states the deamidation status, not just a purity percentage. This is the identity check unique to Tα1.

The Tα1 verification angle →

Don't confuse it with Thymosin Beta-4

Thymosin alpha-1 (a 28-residue immune peptide) and Thymosin Beta-4 — the parent of TB-500 — share a family name but are entirely different molecules with different sequences, sizes, and research interest. A dosing reference for one says nothing about the other. Titan stocks a TB-500 vial; it does not stock thymosin alpha-1, and the two should never be dosed off the same figure.

See the in-stock TB-500 →

Research-use framing

These figures describe doses used in thymosin alpha-1 research, reproduced strictly as a laboratory reference for in-vitro and modelling work — not instructions for human use. Thymalfasin is a prescription compound in the jurisdictions where it is approved; Titan does not sell it and supplies only research-use-only reagents, not for human or animal consumption. Nothing here is medical or dosing advice.

Research-use policy →

The detail, in plain terms

The thymosin alpha-1 reference, in one table.

Tα1's dosing is a fixed amount on a set rhythm, defined by its role as a sustained immune signal rather than an acute pulse. These are the variables a researcher weighs when modelling it — reproduced as a reference, not a human protocol. Titan does not stock thymosin alpha-1.

Compound: Thymosin alpha-1 (thymalfasin, Tα1) — 28-residue, N-acetylated peptide.
Research dose: 1.6 mg subcutaneous twice weekly; wider reported range ~0.8–6.4 mg per dose.
Timing: Twice-weekly fixed schedule, studied over ~24 weeks — not a titration ladder.
Route: Subcutaneous injection (reconstituted from lyophilized powder).
Reconstitution: 10 mg vial + 2.5 mL BAC water → 4 mg/mL (0.4 mL ≈ 1.6 mg).
COA focus: Confirm the N-terminal acetyl cap + full 28-mer by MS — a purity % alone misses it.
Titan catalog: Not stocked. Titan carries TB-500 (a different thymosin-family molecule).

Questions researchers ask

Before you order.

What is the research dosage of thymosin alpha-1?: The dosing references converge on 1.6 mg given subcutaneously twice weekly, with a wider reported single-dose range of roughly 0.8 to 6.4 mg across studies. Study protocols have run the 1.6 mg twice-weekly schedule over about 24 weeks. These figures are reproduced strictly as a laboratory research reference and are not a human dosing protocol or medical advice.
Why is thymosin alpha-1 dosed on a schedule rather than titrated up?: Because the research interest is a sustained immunomodulatory signal over weeks rather than an acute pulse or a titration to a tolerance ceiling. That is why the reference is a fixed 1.6 mg twice weekly instead of an escalating ladder like a metabolic incretin.
What should a thymosin alpha-1 COA confirm?: The natural molecule is N-terminally acetylated, and a non-acetylated impostor is about 42 Da lighter — light enough to hide behind a clean HPLC purity peak. A meaningful certificate confirms the acetyl cap and the full 28-residue sequence by mass spectrometry and states the deamidation status, not just a purity percentage.
Is thymosin alpha-1 the same as TB-500?: No. Thymosin alpha-1 is a 28-residue immune peptide; TB-500 is derived from Thymosin Beta-4, a different and larger molecule. They share only a family name, and a dosing reference for one does not transfer to the other. Titan stocks a TB-500 vial but does not stock thymosin alpha-1.
Does Titan sell thymosin alpha-1?: No. Titan does not stock thymosin alpha-1. This page is an informational dosing reference; the honest catalog pointer is Titan's in-house-tested research peptides, and Titan does carry a separate TB-500 vial from the same broad thymosin family.